Hormonrezisztencia emlorákban - A befolyásolás lehetoségei

Translated title of the contribution: Hormone resistance, and its modulation

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Acquired hormone resistance is a reversible adaptative change of hormone-sensitive breast tumors promoting survival by changes in the balance and communication between estrogen receptor and growth factor signaling. The mechanisms of hormone resistance induced by various hormone therapies are different, however, their common feature is the dominance of growth factor signaling with the consequences of enhanced proliferation and decreased apoptosis. In case of tamoxifen or selective estrogen receptor modulator resistance, the agents' enhanced agonistic activity occurs. The increased expression of certain estrogen receptor coactivators may play an important role. The essential of hormone resistance after estrogen deprivation is estrogen hypersensitivity, which is a consequence of the enhanced activity of the membrane-associated estrogen receptor and its influence on the growth factor signaling. The integration of cell surface growth factor receptor or growth factor signaltransduction blocking agents like tyrosin kinase, MARK, mTOR, PI3K or farnesyl transferase inhibitors into hormone therapies may prevent or treat hormone resistance. The other possibility is to use the hormone therapies sequentially. A new promising agent is the pure antiestrogen fulvestrant which targets the estrogen receptor located in both the membrane or the nucleus. Also, estrogen therapy may revert hormone resistance. The use of predictive markers may promote treatment choice and indicate application of targeted therapies.

Original languageHungarian
Pages (from-to)731-737
Number of pages7
JournalOrvosi Hetilap
Volume146
Issue number16
Publication statusPublished - 2005

Fingerprint

Hormones
Estrogen Receptors
Intercellular Signaling Peptides and Proteins
Estrogens
Selective Estrogen Receptor Modulators
Therapeutics
Estrogen Receptor Modulators
Membranes
Growth Factor Receptors
Tamoxifen
Transferases
Phosphatidylinositol 3-Kinases
Hypersensitivity
Phosphotransferases
Apoptosis
Breast Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hormonrezisztencia emlorákban - A befolyásolás lehetoségei. / Kahán, Z.; Thurzó, L.

In: Orvosi Hetilap, Vol. 146, No. 16, 2005, p. 731-737.

Research output: Contribution to journalArticle

@article{be00b05a938442f09017ea561cc473b1,
title = "Hormonrezisztencia emlor{\'a}kban - A befoly{\'a}sol{\'a}s lehetos{\'e}gei",
abstract = "Acquired hormone resistance is a reversible adaptative change of hormone-sensitive breast tumors promoting survival by changes in the balance and communication between estrogen receptor and growth factor signaling. The mechanisms of hormone resistance induced by various hormone therapies are different, however, their common feature is the dominance of growth factor signaling with the consequences of enhanced proliferation and decreased apoptosis. In case of tamoxifen or selective estrogen receptor modulator resistance, the agents' enhanced agonistic activity occurs. The increased expression of certain estrogen receptor coactivators may play an important role. The essential of hormone resistance after estrogen deprivation is estrogen hypersensitivity, which is a consequence of the enhanced activity of the membrane-associated estrogen receptor and its influence on the growth factor signaling. The integration of cell surface growth factor receptor or growth factor signaltransduction blocking agents like tyrosin kinase, MARK, mTOR, PI3K or farnesyl transferase inhibitors into hormone therapies may prevent or treat hormone resistance. The other possibility is to use the hormone therapies sequentially. A new promising agent is the pure antiestrogen fulvestrant which targets the estrogen receptor located in both the membrane or the nucleus. Also, estrogen therapy may revert hormone resistance. The use of predictive markers may promote treatment choice and indicate application of targeted therapies.",
keywords = "Aromatase inhibitors, Breast cancer, Estrogen hypersensitivity, Estrogen receptor, Fulvestrant, Hormone resistance, Hormone sensitivity, Tamoxifen, Targeted therapy",
author = "Z. Kah{\'a}n and L. Thurz{\'o}",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "731--737",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "16",

}

TY - JOUR

T1 - Hormonrezisztencia emlorákban - A befolyásolás lehetoségei

AU - Kahán, Z.

AU - Thurzó, L.

PY - 2005

Y1 - 2005

N2 - Acquired hormone resistance is a reversible adaptative change of hormone-sensitive breast tumors promoting survival by changes in the balance and communication between estrogen receptor and growth factor signaling. The mechanisms of hormone resistance induced by various hormone therapies are different, however, their common feature is the dominance of growth factor signaling with the consequences of enhanced proliferation and decreased apoptosis. In case of tamoxifen or selective estrogen receptor modulator resistance, the agents' enhanced agonistic activity occurs. The increased expression of certain estrogen receptor coactivators may play an important role. The essential of hormone resistance after estrogen deprivation is estrogen hypersensitivity, which is a consequence of the enhanced activity of the membrane-associated estrogen receptor and its influence on the growth factor signaling. The integration of cell surface growth factor receptor or growth factor signaltransduction blocking agents like tyrosin kinase, MARK, mTOR, PI3K or farnesyl transferase inhibitors into hormone therapies may prevent or treat hormone resistance. The other possibility is to use the hormone therapies sequentially. A new promising agent is the pure antiestrogen fulvestrant which targets the estrogen receptor located in both the membrane or the nucleus. Also, estrogen therapy may revert hormone resistance. The use of predictive markers may promote treatment choice and indicate application of targeted therapies.

AB - Acquired hormone resistance is a reversible adaptative change of hormone-sensitive breast tumors promoting survival by changes in the balance and communication between estrogen receptor and growth factor signaling. The mechanisms of hormone resistance induced by various hormone therapies are different, however, their common feature is the dominance of growth factor signaling with the consequences of enhanced proliferation and decreased apoptosis. In case of tamoxifen or selective estrogen receptor modulator resistance, the agents' enhanced agonistic activity occurs. The increased expression of certain estrogen receptor coactivators may play an important role. The essential of hormone resistance after estrogen deprivation is estrogen hypersensitivity, which is a consequence of the enhanced activity of the membrane-associated estrogen receptor and its influence on the growth factor signaling. The integration of cell surface growth factor receptor or growth factor signaltransduction blocking agents like tyrosin kinase, MARK, mTOR, PI3K or farnesyl transferase inhibitors into hormone therapies may prevent or treat hormone resistance. The other possibility is to use the hormone therapies sequentially. A new promising agent is the pure antiestrogen fulvestrant which targets the estrogen receptor located in both the membrane or the nucleus. Also, estrogen therapy may revert hormone resistance. The use of predictive markers may promote treatment choice and indicate application of targeted therapies.

KW - Aromatase inhibitors

KW - Breast cancer

KW - Estrogen hypersensitivity

KW - Estrogen receptor

KW - Fulvestrant

KW - Hormone resistance

KW - Hormone sensitivity

KW - Tamoxifen

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=21744444786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21744444786&partnerID=8YFLogxK

M3 - Article

VL - 146

SP - 731

EP - 737

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 16

ER -